Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Icatibant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 650,838Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Septerna Begin Ph1 Trial of SEP-631 for Mast Cell-Driven Diseases
    Septerna Begin Ph1 Trial of SEP-631 for Mast Cell-Driven Diseases

    21 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/21/3137083/0/en/Septerna-Announces-Dosing-of-the-First-Participants-in-Phase-1-Clinical-Trial-of-SEP-631-an-Oral-Small-Molecule-MRGPRX2-Negative-Allosteric-Modulator-for-the-Treatment-of-Mast-Cell.html

    GLOBENEWSWIRE
    21 Aug 2025
    Share Share
    Orsini Now Provider for SAJAZIR Injection in Acute HAE Attacks
    Orsini Now Provider for SAJAZIR Injection in Acute HAE Attacks

    05 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orsini-now-a-specialty-pharmacy-provider-for-sajazir-icatibant-injection-to-treat-acute-hae-attacks-302295748.html

    PR NEWSWIRE
    05 Nov 2024
    Share Share
    Alembic Pharma Gets USFDA Nod for Generic Hereditary Angioedema Injection
    Alembic Pharma Gets USFDA Nod for Generic Hereditary Angioedema Injection

    17 Jun 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-generic-injection-to-treat-hereditary-angioedema/articleshow/111055088.cms

    ECONOMICTIMES
    17 Jun 2024
    Share Share
    Alembic's Generic Icatibant Acetate Receives Approval in US
    Alembic's Generic Icatibant Acetate Receives Approval in US

    14 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213773

    FDA
    14 Jun 2024
    Share Share
    Aurobindo Pharma gets U.S. FDA nod for generic Icatibant injection
    Aurobindo Pharma gets U.S. FDA nod for generic Icatibant injection

    16 Aug 2023

    // THE HINDU

    https://www.thehindu.com/business/aurobindo-pharma-gets-us-fda-nod-for-generic-icatibant-injection/article67202351.ece

    THE HINDU
    16 Aug 2023
    Share Share
    Eugia Pharma's Generic Icatibant Acetate Receives Approval in the U.S.
    Eugia Pharma's Generic Icatibant Acetate Receives Approval in the U.S.

    14 Aug 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213521

    FDA
    14 Aug 2023
    Share Share